Pecularities of immunocytochemical reaction on cytokeratins application in the differential diagnosis of tumor and non-tumor pleurisy and ascites

Abstract

The results of the immunocytochemilal reactions applications with cytokeratins 5/6, 7, 18, 20 and pan-cytokeratins from 81 patients are presented in this article. To evaluate the reaction it is necessary to take into consideration that mesothelial origin cells express both low and high molecular keratins. In differential diagnostics of adenocarcinoma and epiteliod mesothelioma as well as reactive mesothelium it is very important to evaluate immunoreactivity of cytokeratins and the result of reaction of mesothelial and epithelial markers.

Keywords

cytoceratins / immunocytochemical method / pleural and ascetic fluid

References

[1] Глузман Д.Ф., Скляренко Л.М., Надгорная В.А., Крячок И.А. Диагностическая иммуноцитохимия опухолей. Киев: Морион; 2003: 32—5.

[2] Петров С.В., Райхлин Н.Т. Руководство по иммуногистохимической диагностике опухолей человека. Казань; 2004: 302—9.

[3] Listron M.B., Dalton L.W. Comparison of keratin monoclonal antibodies MAR-6, AE1/AE3 and CAM — 5.2. Am. J. Clin. Pathol. 1987; 88: 297.

[4] Report of normal tissue immunohistochemical testing using DacoCyto-mation Mause Anti-Human Cytokeratin, Clone AE1/AE3. DacoCytoma-tion. June 1998.

[5] Prieto V.G., McNutt N.S., Shea C.R., Lugo J. Expression of cytokeratk 10, 17 and 18 in normal and pathological skon asdetected by the monoclonal antibody MNF 116. J. Invest Dermatol. 1993; 100: 547.

[6] Waish C.B., Hamilton V, Curran B., Leader M. Diagnostic applicacion of the cytoceratin MNF 116 in a wide range of sarcomas, carcinomas, and limphomas. J. Pathol. 1993; 167 (Suppl.): 148A.

[7] Gabris S., Kern L. Two color imunostaining of pleural effusions with Ber-EP4 and CK5/6. Cytopathology. 2004; 15 (Suppl. 2): 14.

[8] Shield P. W., Koivurinne K. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. Cytopathology. 2008; 19(4): 218—23.

[9] Мельник ММ. Імуногістохімічні технології діагностики метастазів анонімної пухлини. Світ медицини та біології. 2008; 2: 48—56.

[10] Dejmek A. CE.5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma. Acta Cytol. 2008; 52(5): 579-83.

[11] Pu R.T., Pang Y.,Michael C.W Utility of WT-1, p63, MOC31, mesothelin, and ytokeratin (К903 and CE.5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagnost. Cytopathol. 2008; 36 (1): 20—5.

[12] Chu P.G., Weiss L.M. Expression of cytokeratin 5/6 in epithelial neoplasms: An immunohistochemical study of 509 cases. Mod. Pathol. 2002; 15: 6—10.

[13] Chu P. G., Wu E., Weiss L. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod. Pathol. 2000; 13(9): 962—72.

[14] Tot T. Cytokeratyns 20 and 7 as biomarkers usefulness in discriminating primary from metastatic adenocarcinom. Eur. J. Cancer. 2002. 38(6): 758-63.

[15] Fetsch P.A., Abati A. Immunocytochemistry in effusion cytology: a contemporary review. Cancer. 2001; 93(5): 293—308.

[16] Tot T. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas. Cancer. 2001; 92(10): 2728—32.

RIGHTS & PERMISSIONS

Eco-Vector